Intrinsic stability, oligomerization, and amyloidogenicity of HDL-free serum amyloid A

Advances in Experimental Medicine and Biology

Volumn 855, Issue , 2015, Pages 117-134

  Colón, Wilfredo ^a   Javier Aguilera, J ^a   Srinivasan, Saipraveen ^a  

^a Research Rensselaer Polytechnic Institute   (United States)

Author keywords

Acute phase; Amyloidosis; High density lipoprotein; Infl ammation; Intrinsically disordered protein; Prion like infectivity

Indexed keywords

GLYCOSAMINOGLYCAN; HIGH DENSITY LIPOPROTEIN; ISOPROTEIN; SERUM AMYLOID A; AMYLOID; BIOPOLYMER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AMYLOIDOSIS; ARTICLE; BIOACCUMULATION; DISEASE ASSOCIATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOLECULAR DYNAMICS; NONHUMAN; OLIGOMERIZATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN REFOLDING; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DISEASE MODEL; METABOLISM; MOUSE; PROTEIN CONFORMATION;

MURINAE;

AMYLOID; ANIMALS; BIOPOLYMERS; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; HUMANS; MICE; PROTEIN CONFORMATION; SERUM AMYLOID A PROTEIN;

EID: 84936762240     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-17344-3_5     Document Type: Article

References (102)

1. Aguilera JJ, Zhang F, Beaudet JM, Linhardt RJ, Colon W (2014) Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A. Biochimie 104:70–80
2. Ancsin JB, Kisilevsky R (1999) The heparin/heparan sulfate- binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 274:7172–7181
3. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner M (1982) Further characterization of amyloidenhancing factor. Lab Invest 47:139–146
4. Benditt EP, Eriksen N (1977) Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci U S A 74:4025–4028
5. Bourgault S, Solomon JP, Reixach N, Kelly JW (2011) Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry 50:1001–1015
6. Breinig S, Kervinen J, Stith L, Wasson AS, Fairman R, Wlodawer A, Zdanov A, Jaffe EK (2003) Control of tetrapyrrole biosynthesis by alternate quaternary forms of porphobilinogen synthase. Nat Struct Biol 10:757–763
7. Chung TF, Sipe JD, McKee A, Fine RE, Schreiber BM, Liang JS, Johnson RJ (2000) Serum amyloid A in Alzheimer’s disease brain is predominantly localized to myelin sheaths and axonal membrane. Amyloid 7:105–110
8. Cross AJ, Jeffries CM, Trewhella J, Matthews JM (2010) LIM domain binding proteins 1 and 2 have different oligomeric states. J Mol Biol 399:133–144
9. Cuanalo-Contreras K, Mukherjee A, Soto C (2013) Role of protein misfolding and proteostasis deficiency in protein misfolding diseases and aging. Int J Cell Biol 2013:1–10
10. Cunnane G (2001) Amyloid precursors and amyloidosis in infl ammatory arthritis. Curr Opin Rheumatol 13:67–73
11. de Beer MC, de Beer FC, McCubbin WD, Kay CM, Kindy MS (1993) Structural prerequisites for serum amyloid A fibril formation. J Biol Chem 268:20606–20612
12. Derebe MG, Zlatkov CM, Gattu S, Ruhn KA, Vaishnava S, Diehl GE, MacMillan JB, Williams NS, Hooper LV (2014) Serum amyloid A is a retinol binding protein that transports retinol during bacterial infection. Elife 3:e03206
13. Egashira M, Takase H, Yamamoto I, Tanaka M, Saito H (2011) Identification of regions responsible for heparin- induced amyloidogenesis of human serum amyloid A using its fragment peptides. Arch Biochem Biophys 511:101–106
14. Eklund KK, Niemi K, Kovanen PT (2012) Immune functions of serum amyloid A. Crit Rev Immunol 32:335–348
15. Elimova E, Kisilevsky R, Szarek WA, Ancsin JB (2004) Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 18:1749–1751
16. Elimova E, Kisilevsky R, Ancsin JB (2009) Heparan sulfate promotes the aggregation of HDL-associated serum amyloid A: evidence for a proamyloidogenic histidine molecular switch. FASEB J 23:3436–3448
17. Ericsson LH, Eriksen N, Walsh KA, Benditt EP (1987) Primary structure of duck amyloid protein A. The form deposited in tissues may be identical to its serum precursor. FEBS Lett 218:11–16
18. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to infl ammation. N Engl J Med 340:448–454
19. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358:24–29
20. Guerrero-Munoz MJ, Castillo-Carranza DL, Kayed R (2014) Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem Pharmacol 88:468–478
21. Guo JT, Yu J, Grass D, de Beer FC, Kindy MS (2002) Infl ammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J Neurosci 22:5900–5909
22. Hazenberg BP, van Rijswijk MH (2000) Where has secondary amyloid gone? Ann Rheum Dis 59:577–579
23. Hoffman JS, Ericsson LH, Eriksen N, Walsh KA, Benditt EP (1984) Murine tissue amyloid protein AA. NH2- terminal sequence identity with only one of two serum amyloid protein (ApoSAA) gene products. J Exp Med 159:641–646
24. Husby G (1998) Treatment of amyloidosis and the rheumatologist. State of the art and perspectives for the future. Scand J Rheumatol 27:161–165
25. Husebekk A, Skogen B, Husby G, Marhaug G (1985) Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 21:283–287
26. Immonen K, Finne P, Gronhagen-Riska C, Pettersson T, Klaukka T, Kautiainen H, Hakala M (2011) A marked decline in the incidence of renal replacement therapy for amyloidosis associated with infl ammatory rheumatic diseases – data from nationwide registries in Finland. Amyloid 18:25–28
27. Inoue S, Kawano H, Ishihara T, Maeda S, Ohno S (2005) Formation of experimental murine AA amyloid fibrils in SAP-deficient mice: high resolution ultrastructural study. Amyloid 12:157–163
28. Ishihara T (1973) Experimental amyloidosis using silver nitrate – electron microscopic study on the relationship between silver granules, amyloid fibrils and reticuloendothelial system. Acta Pathol Jpn 23:439–464
29. Jahn TR, Radford SE (2008) Folding versus aggregation: polypeptide conformations on competing pathways. Arch Biochem Biophys 469:100–117
30. Jimenez JL, Tennent G, Pepys M, Saibil HR (2001) Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy. J Mol Biol 311:241–247
31. Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU (2013) Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem 82:323–355
32. Kintzer AF, Thoren KL, Sterling HJ, Dong KC, Feld GK, Tang II, Zhang TT, Williams ER, Berger JM, Krantz BA (2009) The protective antigen component of anthrax toxin forms functional octameric complexes. J Mol Biol 392:614–629
33. Kisilevsky R, Boudreau L (1983) Kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy. Lab Invest 48:53–59
34. Kisilevsky R, Fraser P (1996) Proteoglycans and amyloid fibrillogenesis. Ciba Found Symp 199:58–67 (discussion 68-72, 90-103)
35. Kisilevsky R, Manley PN (2012) Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid 19:5–14
36. Kisilevsky R, Subrahmanyan L (1992) Serum amyloid A changes high density lipoprotein’s cellular affinity. A clue to serum amyloid A’s principal function. Lab Invest 66:778–785
37. Kodali R, Wetzel R (2007) Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol 17:48–57
38. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361–2371
39. Landman WJ (1999) Amyloid arthropathy in chickens. Vet Q 21:78–82
40. Levin M, Franklin EC, Frangione B, Pras M (1972) The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J Clin Invest 51:2773–2776
41. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U (2005) In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci U S A 102:6473–6477
42. Liang JS, Schreiber BM, Salmona M, Phillip G, Gonnerman WA, de Beer FC, Sipe JD (1996) Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. J Lipid Res 37:2109–2116
43. Liang JS, Sloane JA, Wells JM, Abraham CR, Fine RE, Sipe JD (1997) Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer’s disease brain. Neurosci Lett 225:73–76
44. Liepnieks JJ, Kluve-Beckerman B, Benson MD (1995) Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1. Biochim Biophys Acta 1270:81–86
45. Lu J, Yu Y, Zhu I, Cheng Y, Sun PD (2014) Structural mechanism of serum amyloid A-mediated infl ammatory amyloidosis. Proc Natl Acad Sci U S A 111:5189–5194
46. Lundmark K, Westermark GT, Nystrom S, Murphy CL, Solomon A, Westermark P (2002) Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci U S A 99:6979–6984
47. Malle E, Sodin-Semrl S, Kovacevic A (2009) Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66:9–26
48. Manning M, Colon W (2004) Structural basis of protein kinetic stability: resistance to sodium dodecyl sulfate suggests a central role for rigidity and a bias toward beta-sheet structure. Biochemistry 43:11248–11254
49. Martin DJ, Ramirez-Alvarado M (2011) Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction. Biophys Chem 158:81–89
50. McAdam KP, Sipe JD (1976) Murine model for human secondary amyloidosis: genetic variability of the acute-phase serum protein SAA response to endotoxins and casein. J Exp Med 144:1121–1127
51. Meek RL, Hoffman JS, Benditt EP (1986) Amyloidogenesis. One serum amyloid A isotype is selectively removed from the circulation. J Exp Med 163:499–510
52. Meek RL, Urieli-Shoval S, Benditt EP (1994) Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci U S A 91:3186–3190
53. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret J-M, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M (2006) Exogenous induction of cerebral beta- amyloidogenesis is governed by agent and host. Science 313:1781–1784
54. Miyagi Y, Matsumura Y, Sagami H (2007) Human geranylgeranyl diphosphate synthase is an octamer in solution. J Biochem 142:377–381
55. Mutru O, Laakso M, Isomaki H, Koota K (1985) Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 290:1797–1799
56. Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M (2006) Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford) 45:43–49
57. Noborn F, Ancsin JB, Ubhayasekera W, Kisilevsky R, Li JP (2012) Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation. J Biol Chem 287:25669–25677
58. Obici L, Merlini G (2012) AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly 142:w13580
59. Patel H, Bramall J, Waters H, De Beer MC, Woo P (1996) Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by site-directed mutagenesis. Biochem J 318(Pt 3):1041–1049
60. Patke S, Maheshwari R, Litt J, Srinivasan S, Aguilera JJ, Colon W, Kane RS (2012) Infl uence of the carboxy terminus of serum amyloid A on protein oligomerization, misfolding, and fibril formation. Biochemistry 51:3092–3099
61. Patke S, Srinivasan S, Maheshwari R, Srivastava SK, Aguilera JJ, Colon W, Kane RS (2013) Characterization of the oligomerization and aggregation of human serum amyloid a. PLoS One 8:e64974
62. Pellarin R, Schuetz P, Guarnera E, Cafl isch A (2010) Amyloid fibril polymorphism is under kinetic control. J Am Chem Soc 132:14960–14970
63. Pepys MB (2006) Amyloidosis. Annu Rev Med 57:223–241
64. Rocken C, Shakespeare A (2002) Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 440:111–122
65. Seilheimer B, Bohrmann B, BondolfiL, Muller F, Stuber D, Dobeli H (1997) The toxicity of the Alzheimer’s beta-amyloid peptide correlates with a distinct fiber morphology. J Struct Biol 119:59–71
66. Shiroo M, Kawahara E, Nakanishi I, Migita S (1987) Specific deposition of serum amyloid A protein 2 in the mouse. Scand J Immunol 26:709–716
67. Simms RW, Prout MN, Cohen AS (1994) The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 8:627–634
68. Simons JP, Al-Shawi R, Ellmerich S, Speck I, Aslam S, Hutchinson WL, Mangione PP, Disterer P, Gilbertson JA, Hunt T, Millar DJ, Minogue S, Bodin K, Pepys MB, Hawkins PN (2013) Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci U S A 110:16115–16120
69. Sipe JD (1992) Amyloidosis. Annu Rev Biochem 61:947–975
70. Sipe J (1999) Revised nomenclature for serum amyloid A (SAA). Nomenclature committee of the international society of amyloidosis. Part 2. Amyloid 6:67–70
71. Sipe JD, Carreras I, Gonnerman WA, Cathcart ES, de Beer MC, de Beer FC (1993) Characterization of the inbred CE/J mouse strain as amyloid resistant. Am J Pathol 143:1480–1485
72. Skinner M, Shirahama T, Benson MD, Cohen AS (1977) Murine amyloid protein AA in casein-induced experimental amyloidosis. Lab Invest 36:420–427
73. Sletten K, Husby G (1974) The complete amino-acid sequence of non-immunoglobulin amyloid fibril protein AS in rheumatoid arthritis. Eur J Biochem 41:117–125
74. Snow AD, Bramson R, Mar H, Wight TN, Kisilevsky R (1991) A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem 39:1321–1330
75. Solomon JP, Bourgault S, Powers ET, Kelly JW (2011) Heparin binds 8 kDa gelsolin cross-beta-sheet oligomers and accelerates amyloidogenesis by hastening fibril extension. Biochemistry 50:2486–2498
76. Srinivasan S, Patke S, Wang Y, Ye Z, Litt J, Srivastava SK, Lopez MM, Kurouski D, Lednev IK, Kane RS, Colon W (2013) Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2. J Biol Chem 288:2744–2755
77. Stefani M (2012) Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer’s disease and other diseases with amyloid deposits. Prog Neurobiol 99:226–245
78. Steinmetz A, Hocke G, Saile R, Puchois P, Fruchart JC (1989) Infl uence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1006:173–178
79. Tam SP, Flexman A, Hulme J, Kisilevsky R (2002) Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J Lipid Res 43:1410–1420
80. Tanaka M, Collins SR, Toyama BH, Weissman JS (2006) The physical basis of how prion conformations determine strain phenotypes. Nature 442:585–589
81. Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y (1998) Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem 46:1377–1384
82. Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7:64–69
83. Uversky VN (2009) Intrinsic disorder in proteins associated with neurodegenerative diseases. Front Biosci 14:5188–5238
84. Uversky VN (2013) Unusual biophysics of intrinsically disordered proteins. Biochim Biophys Acta 1834:932–951
85. van der Hilst JC (2011) Recent insights into the pathogenesis of type AA amyloidosis. Sci World J 11:641–650
86. van der Westhuyzen DR, de Beer FC, Webb NR (2007) HDL cholesterol transport during infl ammation. Curr Opin Lipidol 18:147–151
87. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM (2003) Heparan sulphate proteoglycans in Alzheimer’s disease and amyloid-related disorders. Lancet Neurol 2:482–492
88. Wang L, Colon W (2005) Urea-induced denaturation of apolipoprotein serum amyloid A reveals marginal stability of hexamer. Protein Sci 14:1811–1817
89. Wang L, Lashuel HA, Walz T, Colon W (2002) Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel. Proc Natl Acad Sci U S A 99:15947–15952
90. Wang L, Lashuel HA, Colon W (2005) From hexamer to amyloid: marginal stability of apolipoprotein SAA2.2 leads to in vitro fibril formation at physiological temperature. Amyloid 12:139–148
91. Wang Y, Srinivasan S, Ye Z, Javier Aguilera J, Lopez MM, Colon W (2011) Serum amyloid A 2.2 refolds into a octameric oligomer that slowly converts to a more stable hexamer. Biochem Biophys Res Commun 407:725–729
92. Wang B, Tan YX, Jia J, Digre A, Zhang X, Vlodavsky I, Li JP (2012) Accelerated resolution of AA amyloid in heparanase knockout mice is associated with matrix metalloproteases. PLoS One 7:e39899
93. Webb NR, de Beer MC, van der Westhuyzen DR, Kindy MS, Banka CL, Tsukamoto K, Rader DL, de Beer FC (1997) Adenoviral vector-mediated overexpression of serum amyloid A in apoA-I-deficient mice. J Lipid Res 38:1583–1590
94. Westermark GT, Sletten K, Westermark P (1989) Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol 30:605–613
95. Westermark GT, Engstrom U, Westermark P (1992) The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun 182:27–33
96. Westermark P, Lundmark K, Westermark GT (2009) Fibrils from designed non-amyloid-related synthetic peptides induce AA-amyloidosis during infl ammation in an animal model. PLoS One 4:e6041
97. Westermark GT, Fandrich M, Westermark P (2015) AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 10:321–344
98. Woldemeskel M (2012) A concise review of amyloidosis in animals. Vet Med Int 2012:427296
99. Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD (1995) In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: possible protection against amyloid fibril formation. Scand J Immunol 41:570–574
100. Ye Z, Bayron Poueymiroy D, Aguilera JJ, Srinivasan S, Wang Y, Serpell LC, Colon W (2011) Infl ammation protein SAA2.2 spontaneously forms marginally stable amyloid fibrils at physiological temperature. Biochemistry 50:9184–9191
101. Zhang X, Li JP (2010) Heparan sulfate proteoglycans in amyloidosis. Prog Mol Biol Transl Sci 93:309–334
102. Zhang B, Une Y, Fu X, Yan J, Ge F, Yao J, Sawashita J, Mori M, Tomozawa H, Kametani F, Higuchi K (2008) Fecal transmission of AA amyloidosis in the cheetah contributes to high incidence of disease. Proc Natl Acad Sci U S A 105:7263–7268